{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:23:44Z","timestamp":1759710224795,"version":"build-2065373602"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.mehy.2021.110619","type":"journal-article","created":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T12:00:10Z","timestamp":1622548810000},"page":"110619","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["A tale of two diseases: Sarcoidosis, COVID-19 and new therapeutic options with dual RAS inhibition and tetanus-diphtheria vaccine"],"prefix":"10.1016","volume":"152","author":[{"given":"Demircan","family":"Ozbalci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mehy.2021.110619_b0005","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2001316","article-title":"Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia","author":"Li","year":"2020","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.mehy.2021.110619_b0010","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1056\/NEJMoa030781","article-title":"A novel coronavirus associated with severe acute respiratory syndrome","volume":"348","author":"Ksiazek","year":"2003","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.mehy.2021.110619_b0015","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1211721","article-title":"Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia","volume":"367","author":"Zaki","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mehy.2021.110619_b0020","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical Characteristics of Coronavirus Disease 2019 in China","author":"Guan","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mehy.2021.110619_b0025","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases from the Chinese Center for Disease Control and Prevention","author":"Wu","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.mehy.2021.110619_b0030","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.4344","article-title":"Coronavirus Disease 2019 (COVID-19) in Italy","author":"Livingston","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.mehy.2021.110619_b0035","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.4031","article-title":"Critical Care Utilization for the COVID-19 Outbreak in Lombardy, Italy: Early Experience and Forecast During an Emergency Response","author":"Grasselli","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.mehy.2021.110619_b0040","doi-asserted-by":"crossref","unstructured":"Ko WC, Rolain JM, Lee NY, Chen PL, Huang CT, Lee PI, et al. Arguments in favour of remdesivir for treating SARS-CoV-2 infections. Int J Antimicrob Agents. 2020 Apr;55(4):105933. doi: 10.1016\/j.ijantimicag.2020.105933. Epub 2020 Mar 6. PMID: 32147516; PMCID: PMC7135364.","DOI":"10.1016\/j.ijantimicag.2020.105933"},{"key":"10.1016\/j.mehy.2021.110619_b0045","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2001282","article-title":"A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe COVID-19","author":"Cao","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mehy.2021.110619_b0050","doi-asserted-by":"crossref","unstructured":"Liu J,Cao R,Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibitingSARS-CoV-2infection in vitro. Cell Discov.2020 Mar 18;6:16. doi: 10.1038\/s41421-020-0156-0. eCollection 2020.","DOI":"10.1038\/s41421-020-0156-0"},{"key":"10.1016\/j.mehy.2021.110619_b0055","first-page":"05938","article-title":"New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?","volume":"11","author":"Devaux","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.mehy.2021.110619_b0060","article-title":"Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19?","volume":"13","author":"Baron","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.mehy.2021.110619_b0065","doi-asserted-by":"crossref","unstructured":"Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016\/j.ijantimicag.2020.105949. Epub 2020 Mar 20. PMID: 32205204; PMCID: PMC7102549.","DOI":"10.1016\/j.ijantimicag.2020.105949"},{"issue":"1","key":"10.1016\/j.mehy.2021.110619_b0070","doi-asserted-by":"crossref","first-page":"58","DOI":"10.5582\/ddt.2020.01012","article-title":"Discovering drugs to treat coronavirus disease 2019 (COVID-19)","volume":"14","author":"Dong","year":"2020","journal-title":"Drug Discov Ther."},{"issue":"8","key":"10.1016\/j.mehy.2021.110619_b0075","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1080\/23744235.2020.1769177","article-title":"Re-infection by COVID-19: a real threat for the future management of pandemia?","volume":"52","author":"Bongiovanni","year":"2020","journal-title":"Infect Dis (Lond)."},{"key":"10.1016\/j.mehy.2021.110619_b0080","unstructured":"To KK, Hung IF, Ip JD, Chu AW, Chan WM, Tam AR, et al. COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing. Clin Infect Dis. 2020 Aug 25: ciaa1275. doi: 10.1093\/cid\/ciaa1275. Epub ahead of print. PMID: 32840608; PMCID: PMC7499500."},{"key":"10.1016\/j.mehy.2021.110619_b0085","doi-asserted-by":"crossref","unstructured":"Edridge AWD, Kaczorowska J, Hoste ACR, Bakker M, Klein M, Loens K, et al. Seasonal coronavirus protective immunity is short-lasting. Nat Med. 2020 Sep 14. doi: 10.1038\/s41591-020-1083-1. Epub ahead of print. PMID: 32929268.","DOI":"10.1038\/s41591-020-1083-1"},{"key":"10.1016\/j.mehy.2021.110619_b0090","unstructured":"Vabret N, Britton GJ, Gruber C, Hegde S, Kim J, Kuksin M, et al. Sinai Immunology Review Project. Immunology of COVID-19: Current State of the Science. Immunity. 2020 Jun 16;52(6):910-941. doi: 10.1016\/j.immuni.2020.05.002. Epub 2020 May 6. PMID: 32505227; PMCID: PMC7200337."},{"key":"10.1016\/j.mehy.2021.110619_b0095","doi-asserted-by":"crossref","unstructured":"Felsenstein S, Herbert JA, McNamara PS, Hedrich CM. COVID-19: Immunology and treatment options. Clin Immunol. 2020 Jun; 215:108448. doi: 10.1016\/j.clim.2020.108448. Epub 2020 Apr 27. PMID: 32353634; PMCID: PMC7185015.","DOI":"10.1016\/j.clim.2020.108448"},{"issue":"suppl","key":"10.1016\/j.mehy.2021.110619_b0100","first-page":"S9","article-title":"SARS: epidemiology","volume":"8","author":"Chan-Yeung","year":"2003","journal-title":"Respirology"},{"issue":"1","key":"10.1016\/j.mehy.2021.110619_b0105","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.antiviral.2013.08.014","article-title":"Receptor recognition and cross-species infections of SARS coronavirus","volume":"100","author":"Li","year":"2013","journal-title":"Antiviral Res"},{"key":"10.1016\/j.mehy.2021.110619_b0110","unstructured":"Imai Y,Kuba K,Ohto-Nakanishi T,Penninger JM. Angiotensin-converting enzyme 2 (ACE2) in disease pathogenesis."},{"issue":"6","key":"10.1016\/j.mehy.2021.110619_b0115","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2147\/VHRM.S11816","article-title":"Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination","volume":"9","author":"Cagnoni","year":"2010","journal-title":"Vasc Health Risk Manag."},{"issue":"7","key":"10.1016\/j.mehy.2021.110619_b0120","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/labinvest.2017.32","article-title":"Angiotensin-converting enzyme affects the presentation of MHC class II antigens","volume":"97","author":"Zhao","year":"2017","journal-title":"Lab Invest"},{"issue":"19","key":"10.1016\/j.mehy.2021.110619_b0125","first-page":"4089","article-title":"Local bone marrow renin-angiotensin system in the genesis of leukemia and other malignancies","volume":"20","author":"Haznedaroglu","year":"2016","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.mehy.2021.110619_b0130","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1253\/circj.CJ-09-0324","article-title":"Angiotensin II receptor blocker, valsartan, increases myocardial blood volume and regresses hypertrophy in hypertensive patients","volume":"73","author":"Komatsu","year":"2009","journal-title":"Circ J"},{"key":"10.1016\/j.mehy.2021.110619_b0135","doi-asserted-by":"crossref","first-page":"33238","DOI":"10.1074\/jbc.M002615200","article-title":"A human homolog of angiotensin-converting enzyme: Cloning and functional expression as a captopril-insensitive carboxypeptidase","volume":"275","author":"Tipnis","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.mehy.2021.110619_b0140","doi-asserted-by":"crossref","first-page":"4703","DOI":"10.1210\/en.2004-0443","article-title":"The novel angiotensin-converting enzyme (ACE) homolog, ACE2, is selectively expressed by adult Leydig cells of the testis","volume":"145","author":"Douglas","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.mehy.2021.110619_b0145","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nature02145","article-title":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus","volume":"426","author":"Li","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.mehy.2021.110619_b0150","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nm1267","article-title":"A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus- induced lung injury","volume":"11","author":"Kuba","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.mehy.2021.110619_b0155","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature03712","article-title":"Angiotensin- converting enzyme 2 protects from severe acute lung failure","volume":"436","author":"Imai","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.mehy.2021.110619_b0160","doi-asserted-by":"crossref","unstructured":"Sriram K, Insel PA. A hypothesis for pathobiology and treatment of COVID-19: The centrality of ACE1\/ACE2 imbalance. Br J Pharmacol. 2020 Apr 24. doi: 10.1111\/bph.15082. Epub ahead of print. PMID: 32333398.","DOI":"10.1111\/bph.15082"},{"key":"10.1016\/j.mehy.2021.110619_b0165","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI114844","article-title":"An insertion\/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels","volume":"86","author":"Rigat","year":"1990","journal-title":"J Clin Invest"},{"key":"10.1016\/j.mehy.2021.110619_b0170","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1164\/rccm.2108086","article-title":"Angiotensin converting enzyme insertion\/ deletion polymorphism is associated with susceptibility and outcome in acute respiratory distress syndrome","volume":"166","author":"Marshall","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.mehy.2021.110619_b0175","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1097\/01.CCM.0000206107.92476.39","article-title":"Polymorphism of the angiotensin-converting enzyme gene affects the outcome of acute respiratory distress syndrome","volume":"34","author":"Jerng","year":"2006","journal-title":"Crit Care Med"},{"issue":"7","key":"10.1016\/j.mehy.2021.110619_b0180","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00127-20","article-title":"Receptor Recognition by the Novel Coronavirus from Wuhan: An Analysis Based on Decade-Long Structural Studies of SARS Coronavirus","volume":"4","author":"Wan","year":"2020","journal-title":"J Virol"},{"key":"10.1016\/j.mehy.2021.110619_b0185","first-page":"E014","article-title":"Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 Pneumonia","volume":"43","author":"Sun","year":"2020","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi."},{"key":"10.1016\/j.mehy.2021.110619_b0190","doi-asserted-by":"crossref","unstructured":"G\u00f3mez J, Albaiceta GM, Garc\u00eda-Clemente M, L\u00f3pez-Larrea C, Amado-Rodr\u00edguez L, Lopez-Alonso I, et al. Angiotensin-converting enzymes (ACE, ACE2) gene variants and COVID-19 outcome. Gene. 2020 Aug 31; 762:145102. doi: 10.1016\/j.gene.2020.145102. Epub ahead of print. PMID: 32882331; PMCID: PMC7456966.","DOI":"10.1016\/j.gene.2020.145102"},{"issue":"2","key":"10.1016\/j.mehy.2021.110619_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.jamcollsurg.2015.03.051","article-title":"Angiotensin Inhibition Is Associated with Preservation of T-Cell and Monocyte Function and Decreases Multiple Organ Failure in Obese Trauma Patients","volume":"221","author":"Winfield","year":"2015","journal-title":"J Am Coll Surg"},{"issue":"2","key":"10.1016\/j.mehy.2021.110619_b0200","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.bbrc.2004.10.059","article-title":"ACE inhibition lowers angiotensin II-induced chemokine expression by reduction of NF-kappaB activity and AT1 receptor expression","volume":"325","author":"Schmeisser","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"10.1016\/j.mehy.2021.110619_b0205","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/jmv.25685","article-title":"Coronavirus infections and immune responses","volume":"92","author":"Li","year":"2020","journal-title":"J Med Virol"},{"key":"10.1016\/j.mehy.2021.110619_b0210","doi-asserted-by":"crossref","unstructured":"Afsar B, Kanbay M, Afsar RE. Hypoxia inducible factor-1 protects against COVID-19: A hypothesis. Med Hypotheses. 2020 Oct;143:109857. doi: 10.1016\/j.mehy.2020.109857. Epub 2020 May 20. PMID: 32464493; PMCID: PMC7238987.","DOI":"10.1016\/j.mehy.2020.109857"},{"issue":"1","key":"10.1016\/j.mehy.2021.110619_b0215","doi-asserted-by":"crossref","first-page":"17772","DOI":"10.1038\/s41598-020-74598-5","article-title":"Expression of SARS-CoV-2 entry factors in lung epithelial stem cells and its potential implications for COVID-19","volume":"10","author":"Valyaeva","year":"2020","journal-title":"Sci Rep"},{"issue":"7","key":"10.1016\/j.mehy.2021.110619_b0220","doi-asserted-by":"crossref","DOI":"10.15252\/msb.20209610","article-title":"The protein expression profile of ACE2 in human tissues","volume":"16","author":"Hikmet","year":"2020","journal-title":"Mol Syst Biol"},{"key":"10.1016\/j.mehy.2021.110619_b0225","doi-asserted-by":"crossref","unstructured":"Lukassen S, Chua RL, Trefzer T, Kahn NC, Schneider MA, Muley T, Winter H, Meister M, Veith C, Boots AW, Hennig BP, Kreuter M, Conrad C, Eils R. SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells. EMBO J. 2020 May 18;39(10): e105114. doi: 10.15252\/embj.20105114. Epub 2020 Apr 14. PMID: 32246845; PMCID: PMC7232010.","DOI":"10.15252\/embj.20105114"},{"issue":"5","key":"10.1016\/j.mehy.2021.110619_b0230","first-page":"L1013","article-title":"Captopril inhibits apoptosis in human lung epithelial cells: a potential antifibrotic mechanism","volume":"275","author":"Uhal","year":"1998","journal-title":"Am J Physiol"},{"issue":"2","key":"10.1016\/j.mehy.2021.110619_b0235","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/1097-4652(200011)185:2<253::AID-JCP10>3.0.CO;2-#","article-title":"Apoptosis of lung epithelial cells in response to TNF-alpha requires angiotensin II generation de novo","volume":"185","author":"Wang","year":"2000","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.mehy.2021.110619_b0240","doi-asserted-by":"crossref","unstructured":"Demogines A, Farzan M, Sawyer SL. Evidence for ACE2-utilizing coronaviruses (CoVs) related to severe acute respiratory syndrome CoV in bats. J Virol. 2012 Jun;86(11):6350-3. doi: 10.1128\/JVI.00311-12. Epub 2012 Mar 21. PMID: 22438550; PMCID: PMC3372174.","DOI":"10.1128\/JVI.00311-12"},{"issue":"1","key":"10.1016\/j.mehy.2021.110619_b0245","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/j.1440-1681.2009.05302.x","article-title":"Upregulation of angiotensin-converting enzyme (ACE) 2 in hepatic fibrosis by ACE inhibitors","volume":"37","author":"Huang","year":"2010","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"4","key":"10.1016\/j.mehy.2021.110619_b0250","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00726-014-1889-6","article-title":"Human intestine luminal ACE2 and amino acid transporter expression increased by ACE-inhibitors","volume":"47","author":"Vuille-dit-Bille","year":"2015","journal-title":"Amino Acids"},{"key":"10.1016\/j.mehy.2021.110619_b0255","first-page":"1","article-title":"Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade","volume":"23","author":"Perico","year":"2020","journal-title":"Nephron."},{"key":"10.1016\/j.mehy.2021.110619_b0260","article-title":"angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19","volume":"18","author":"Hypothesis","year":"2020","journal-title":"J Travel Med"},{"issue":"20","key":"10.1016\/j.mehy.2021.110619_b0265","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","article-title":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2","volume":"111","author":"Ferrario","year":"2005","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.mehy.2021.110619_b0270","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1161\/HYPERTENSIONAHA.120.15572","article-title":"Decreased Mortality of COVID-19 With Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Patients with Hypertension: A Meta-Analysis","volume":"76","author":"Guo","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.mehy.2021.110619_b0275","doi-asserted-by":"crossref","unstructured":"Zhang X, Yu J, Pan LY, Jiang HY. ACEI\/ARB use and risk of infection or severity or mortality of COVID-19: A systematic review and meta-analysis. Pharmacol Res. 2020 Aug; 158:104927. doi: 10.1016\/j.phrs.2020.104927. Epub 2020 May 15. PMID: 32422341; PMCID: PMC7227582.","DOI":"10.1016\/j.phrs.2020.104927"},{"key":"10.1016\/j.mehy.2021.110619_b0280","doi-asserted-by":"crossref","unstructured":"Flacco ME, Acuti Martellucci C, Bravi F, Parruti G, Cappadona R, Mascitelli A, et al. Treatment with ACE inhibitors or ARBs and risk of severe\/lethal COVID-19: a meta-analysis. Heart. 2020 Oct;106(19):1519-1524. doi: 10.1136\/heartjnl-2020-317336. Epub 2020 Jul 1. PMID: 32611676; PMCID: PMC7371482.","DOI":"10.1136\/heartjnl-2020-317336"},{"issue":"8","key":"10.1016\/j.mehy.2021.110619_b0285","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrrheum.2011.93","article-title":"Sarcoidosis\u2013scientific progress and clinical challenges","volume":"7","author":"Chen","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.mehy.2021.110619_b0290","doi-asserted-by":"crossref","unstructured":"Loke WS, Herbert C, Thomas PS. Sarcoidosis: Immunopathogenesis and Immunological Markers. Int J Chronic Dis. 2013; 2013:928601. doi: 10.1155\/2013\/928601. Epub 2013 Jul 25. PMID: 26464848; PMCID: PMC4590933.","DOI":"10.1155\/2013\/928601"},{"key":"10.1016\/j.mehy.2021.110619_b0295","doi-asserted-by":"crossref","unstructured":"Miyara M, Amoura Z, Parizot C, Badoual C, Dorgham K, Trad S, et al. The immune paradox of sarcoidosis and regulatory T cells. J Exp Med. 2006 Feb 20;203(2):359-70. doi: 10.1084\/jem.20050648. Epub 2006 Jan 23. Erratum in: J Exp Med. 2006 Feb 20;203(2):477. PMID: 16432251; PMCID: PMC2118208.","DOI":"10.1084\/jem.20050648"},{"key":"10.1016\/j.mehy.2021.110619_b0300","doi-asserted-by":"crossref","unstructured":"Ho LP, Urban BC, Thickett DR, Davies RJ, McMichael AJ. Deficiency of a subset of T-cells with immunoregulatory properties in sarcoidosis. Lancet. 2005 Mar 19-25;365(9464):1062-72. doi: 10.1016\/S0140-6736(05)71143-0. PMID: 15781102.","DOI":"10.1016\/S0140-6736(05)71143-0"},{"issue":"2","key":"10.1016\/j.mehy.2021.110619_b0305","first-page":"110","article-title":"T-lymphocyte activity in HLA-DR17 positive patients with active and clinically recovered sarcoidosis","volume":"20","author":"Planck","year":"2003","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis."},{"issue":"11","key":"10.1016\/j.mehy.2021.110619_b0310","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/infdis\/jiaa150","article-title":"Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia","volume":"221","author":"Wang","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.mehy.2021.110619_b0315","doi-asserted-by":"crossref","unstructured":"Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016\/S0140-6736(20)30183-5. Epub 2020 Jan 24. Erratum in: Lancet. 2020 Jan 30; PMID: 31986264; PMCID: PMC7159299.","DOI":"10.1016\/S0140-6736(20)30183-5"},{"key":"10.1016\/j.mehy.2021.110619_b0320","doi-asserted-by":"crossref","unstructured":"Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020 May;17(5):533-535. doi: 10.1038\/s41423-020-0402-2. Epub 2020 Mar 19. PMID: 32203188; PMCID: PMC7091858.","DOI":"10.1038\/s41423-020-0402-2"},{"key":"10.1016\/j.mehy.2021.110619_b0325","doi-asserted-by":"crossref","unstructured":"Giamarellos-Bourboulis EJ, Netea MG, Rovina N, Akinosoglou K, Antoniadou A, Antonakos N, et al. Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure. Cell Host Microbe. 2020 Jun 10;27(6):992-1000.e3. doi: 10.1016\/j.chom.2020.04.009. Epub 2020 Apr 21. PMID: 32320677; PMCID: PMC7172841.","DOI":"10.1016\/j.chom.2020.04.009"},{"issue":"15","key":"10.1016\/j.mehy.2021.110619_b0330","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1093\/cid\/ciaa248","article-title":"Dysregulation of Immune Response in Patients with Coronavirus 2019 (COVID-19) in Wuhan","volume":"71","author":"Qin","year":"2020","journal-title":"China. Clin Infect Dis."},{"issue":"7","key":"10.1016\/j.mehy.2021.110619_b0335","first-page":"94","article-title":"Effect of Tetanus-diphtheria Vaccine on Immune Response to Hepatitis B Vaccine in Low-responder Individuals","volume":"21","author":"Haghighat","year":"2016","journal-title":"Int J Prev Med."},{"key":"10.1016\/j.mehy.2021.110619_b0340","doi-asserted-by":"crossref","unstructured":"Ietto G. SARS - CoV-2: Reasons of epidemiology of severe ill disease cases and therapeutic approach using trivalent vaccine (tetanus, diphtheria, and Bordetella pertussis). Med Hypotheses. 2020 Aug; 141:109779. doi: 10.1016\/j.mehy.2020.109779. Epub 2020 Apr 22. PMID: 32387756; PMCID: PMC7175879.","DOI":"10.1016\/j.mehy.2020.109779"},{"key":"10.1016\/j.mehy.2021.110619_b0345","article-title":"COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression","volume":"20","author":"Zhou","year":"2020","journal-title":"J Antimicrob Chemother"},{"issue":"369","key":"10.1016\/j.mehy.2021.110619_b0350","article-title":"Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomized controlled trial","volume":"14","author":"Tang","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.mehy.2021.110619_b0355","doi-asserted-by":"crossref","unstructured":"Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for COVID-19. N Engl J Med. 2020 Aug 6;383(6):517-525. doi: 10.1056\/NEJMoa2016638. Epub 2020 Jun 3. PMID: 32492293; PMCID: PMC7289276.","DOI":"10.1056\/NEJMoa2016638"},{"key":"10.1016\/j.mehy.2021.110619_b0360","unstructured":"Rajasingham R, Bangdiwala AS, Nicol MR, Skipper CP, Pastick KA, Axelrod ML, et al. Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial. Clin Infect Dis. 2020 Oct 17: ciaa1571. doi: 10.1093\/cid\/ciaa1571. Epub ahead of print. PMID: 33068425; PMCID: PMC7665393."},{"key":"10.1016\/j.mehy.2021.110619_b0365","doi-asserted-by":"crossref","unstructured":"Ladapo JA, McKinnon JE, McCollough PA, Risch HA. Randomised Controlled Trials of Early Ambulatory Hydoxychloroquine in The Preventation of COVID-19 Infection, Hospitalization; and Death: Meta-Analysis. medRxiv preprint doi: https:\/\/doi.org\/10.1101\/2020.09.30.20204693.","DOI":"10.1101\/2020.09.30.20204693"},{"key":"10.1016\/j.mehy.2021.110619_b0370","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Alb\u00e9niz X, del Amo J, Polo R, Morales-Asencio JS, Hern\u00e1n MA. Brief communication: A meta-analysis of randomized trials of hydroxychloroquine for the prevention of COVID-19. medRxiv preprint doi: Doi: 10.1101\/2020.09.29.20203869.","DOI":"10.1101\/2020.09.29.20203869"},{"issue":"15","key":"10.1016\/j.mehy.2021.110619_b0375","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"ONTARGET Investigators","year":"2008","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.mehy.2021.110619_b0380","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N Engl J Med"},{"issue":"9583","key":"10.1016\/j.mehy.2021.110619_b0385","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0140-6736(07)61124-6","article-title":"Efficacy, and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomized, double-blind trial","volume":"370","author":"Oparil","year":"2007","journal-title":"Lancet"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987721001389?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987721001389?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T19:24:36Z","timestamp":1759692276000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987721001389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":77,"alternative-id":["S0306987721001389"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2021.110619","relation":{},"ISSN":["0306-9877"],"issn-type":[{"type":"print","value":"0306-9877"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A tale of two diseases: Sarcoidosis, COVID-19 and new therapeutic options with dual RAS inhibition and tetanus-diphtheria vaccine","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2021.110619","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110619"}}